Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Pancreatic Neoplasms 2Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Adenocarcinoma Locally Advanced 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1HIV Seropositivity 1Gynecological Cancers 1Colorectal Neoplasms 1Colorectal Liver Metastases 1Carcinoma, Hepatocellular 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Electroporation × Clear all
NCT04526730 2026-02-20

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
17 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡